Medicine
Qinlock 50 mg tablet
Qinlock 50 mg tablet is a prescription medicine containing Ripretinib for oral use, marketed by Deciphera Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursion permitted between 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Ripretinib
- Brand
- Qinlock
- Strength
- 50 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Deciphera Pharmaceuticals
- Manufacturer
- Deciphera Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursion permitted between 15°C to 30°C (59°F to 86°F). Store in the original container with the desiccant to protect from moisture and light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01 Cancer medicines (antineoplastics)
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 May 2020
- Identifiers
- RxCUI 2369397, 2369403DailyMed set ID 9f18e462-03dd-4296-a02a-a0577e3ee78dNDC 73207-101Application NDA213973
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 90 tablet in 1 bottle | 73207-101-30 | Deciphera Pharmaceuticals | 15 May 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ripretinib is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. MedsAcross supplies Ripretinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RipretinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- QINLOCK prescribing information (Deciphera Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Qinlock: European public assessment report (EPAR) · European Medicines Agency
Need Qinlock 50 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.